Journal article
Safety, pharmacodynamics and pharmacokinetics of TPI 1020 in smokers with asthma
Abstract
BACKGROUND: TPI 1020 is a novel compound with potential for anti-neutrophil effects. TPI 1020 exerts its effects by a dual mechanism of action involving corticosteroid activity and controlled donation of nitric oxide.
OBJECTIVES: We assessed the safety, pharmacodynamic and pharmacokinetic activity of ascending doses of TPI 1020 compared to budesonide in asthma.
Authors
Boulet L-P; Lemière C; Gauvreau G; Olivenstein R; Lougheed D; Paradis B; O'Byrne P; Pageau R; Renzi PM
Journal
Respiratory Medicine, Vol. 103, No. 8, pp. 1159–1166
Publisher
Elsevier
Publication Date
August 2009
DOI
10.1016/j.rmed.2009.02.011
ISSN
0954-6111